Alnylam to Invest $250M to Expand Manufacturing Facility in Massachusetts, USA

Specifications:

Name:

Alnylam to Invest $250M to Expand Manufacturing Facility in Massachusetts, USA

Location:

Massachusetts, USA

Company:

Alnylam

Estimated Cost:

$250 Million

Source:

https://investors.alnylam.com/

Introduction:

Alnylam Pharmaceuticals has announced plans to expand its manufacturing plant in Norton, Massachusetts, USA. The company will invest $250 million to add an enzymatic ligation platform for small interfering RNA (siRNA) production. The investment is aimed at meeting rising global demand for RNAi-based therapies and strengthening Alnylam’s manufacturing base in the United States.

Features:

The investment will support the development of what is expected to be the industry’s first fully dedicated, in-house siRNA enzymatic ligation manufacturing plant.

The new platform, called siRELIS™, is designed to increase production capacity while reducing manufacturing timelines, material consumption and overall costs.

It applies a more efficient method for assembling RNA molecules, enabling higher volumes to be produced within a single site while lowering the environmental footprint.

The expansion will improve Alnylam’s ability to support medicines across multiple disease areas, including cardiovascular, metabolic and rare diseases.

Construction at the Norton plant is already underway, with the new manufacturing capabilities expected to become fully operational by late 2027.